Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05095441
Other study ID # MVR-C5252-001
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date March 15, 2023
Est. completion date April 30, 2026

Study information

Verified date October 2022
Source ImmVira Pharma Co. Ltd
Contact ImmVira Pharma Co., LTD
Phone 781-718-5121
Email clinicaltrials@immviragroup.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1 open label, first in human study of C5252 monotherapy designed to determine the safety and tolerability of a single intratumoral (IT) injection of C5252 in patients with recurrent or progressive glioblastoma (GBM).


Description:

This is a Phase 1 open label, first in human study of C5252 monotherapy designed to determine the safety and tolerability of a single IT injection of C5252 in patients with recurrent or progressive GBM. The Part 1 portion of the study is a 3+3 design to evaluate escalating doses of C5252. Total enrollment will depend on the toxicities and/or activity observed, with approximately 36 evaluable participants enrolled. Once the recommended dose (RD) is identified from Part 1, Part 2 Dose Expansion will enroll up to 15 additional participants to further assess the safety, tolerability, and preliminary efficacy of a single IT injection of C5252 monotherapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 51
Est. completion date April 30, 2026
Est. primary completion date April 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: 1. Signed and dated approved informed consent form (ICF) before any protocol-directed screening procedures are performed. 2. Participants must have histopathologically confirmed recurrent supratentorial glioblastoma. 3. Participants must have progressed after at least 1 line but no more than 2 lines of therapy. 4. Evidence of progression by RANO criteria based on MRI scan. 5. Residual lesion must be = 1.0 cm and < 5.5 cm contrast-enhancing in diameter as determined by MRI. 6. Age = 18 years. 7. Karnofsky Performance Score (KPS) = 70. 8. Life expectancy > 12 weeks. 9. Participants must have normal organ and marrow function. 10. Participants must commit to the use of a reliable method of birth control. 11. Resolution of all AEs due to previous therapies to = Grade 1 or baseline. 12. Capable of understanding and complying with protocol requirements. Key Exclusion Criteria: 1. Inability to undergo MRI examination for any reason. 2. A contrast-enhancing brain tumor that does not meet protocol criteria. 3. Prior history of encephalitis, multiple sclerosis, or other CNS infection. 4. Clinical diagnosis of Li-Fraumeni Syndrome or with a known germ line deficit in the retinoblastoma gene or its related pathways. 5. Required steroid increase within 2 weeks prior to date of C5252 administration. 6. Systemic therapy with immunosuppressive agents within 28 days prior to date of C5252 administration. 7. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or any other medical condition that precludes surgery. Also, psychiatric illness/social situations that would limit compliance with study requirements. 8. Bleeding diathesis, or requirement for anticoagulants, or antiplatelet agents, including NSAIDs that cannot be stopped for surgery or biopsy. 9. Current diagnosis of other cancer except in situ cervical cancer, basal or squamous cell carcinoma of the skin. 10. Requires continued concurrent therapy with any drug active against HSV (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). 11. Pregnant or lactating. 12. Prior organ transplantation. 13. Active hepatitis B virus, hepatitis C virus, or a positive serological test at Screening. 14. Active oral herpes lesion at Screening. 15. Congestive heart failure (> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest), or clinically significant cardiac arrhythmias. 16. History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody. 17. Active infection with SARS-CoV-2 virus. 18. Other systemic conditions or organ abnormalities that, in the opinion of the Investigator, may interfere with the conduct and/or interpretation of the current study.

Study Design


Intervention

Biological:
C5252
A single dose of C5252 will be administered up to 2mL as intratumoral injection on Day 1.

Locations

Country Name City State
United States Huntsman Cancer Institute Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
ImmVira Pharma Co. Ltd

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Evaluate blood cytokines Measure blood cytokines using MSD V-Plex Electrochemiluminescence Immunoassay test. Up to 28 days from C5252 injection
Other Evaluate lymphocyte profiling Conduct lymphocyte profiling using PBMC Flow cytometry test. Up to 28 days from C5252 injection
Primary Evaluate the safety and tolerability of C5252 Number of participants in dose escalating cohorts with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities. Up to 28 days from C5252 injection
Primary Characterize Dose Limiting Toxicities Incidence of DLTs Up to 28 days from C5252 injection
Primary Identify the maximum tolerated dose (MTD) and/or the RD of C5252 Incidence of DLTs Up to 28 days from C5252 injection
Secondary Evaluate the PK of C5252 Measure anti-PD-1 antibody concentration in blood using Anti-PD-1 antibody ELISA test and IL-12 concentration in blood using IL-12p70 ELISA test. Up to 2 years from C5252 injection
Secondary Evaluate the viral shedding of C5252 Measure viral shedding of C5252 after intratumoral injection in saliva, nasopharyngeal mucus, and urine using qPCR (quantitative polymerase chain reaction) test. Up to 2 years from C5252 injection
Secondary Overall response rate (ORR) ORR is defined as the proportion of participants who have had a partial response (PR), or complete response (CR) to intervention, based on Investigator Assessment for Neuro-oncology (RANO). Up to 2 years from C5252 injection
Secondary Progression-free survival (PFS) PFS is defined as the time from Day 1 to the first documentation of progressive disease (PD) or death from any cause, whichever occurs first per RANO. Up to 2 years from C5252 injection
Secondary Overall Survival (OS) OS is defined as the time from enrollment to death from any cause. Up to 2 years from C5252 injection
See also
  Status Clinical Trial Phase
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2

External Links